Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Avadel Pharmaceuticals appointed Sev Melkonian as VP of patient services, distribution and reimbursement. Experity appointed ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

Robert F. Kennedy, Jr. – the vaccine skeptic President Donald Trump has nominated to serve as Health and Human Services ...

Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.

The latest health briefs reveal Novo Nordisk's promising obesity treatment and a $7.4 billion Purdue Pharma settlement over ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.